Healthcare Services

Congestive heart failure market insights highlighting growth opportunities

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Congestive Heart Failure (CHF) Market From 2026 To 2030?

The market for congestive heart failure (chf) has experienced robust expansion in recent times. Projections indicate it will expand from $17.1 billion in 2025 to reach $18.31 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. Historically, this growth is primarily due to factors such as an expanding elderly population, the widespread occurrence of cardiovascular disease, restricted choices for outpatient monitoring, numerous hospital re-admissions, and a reliance on hospital-centric care models.

The congestive heart failure (chf) market size is anticipated to experience robust expansion in the upcoming years. Its value is projected to reach $23.79 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period is fueled by an escalating prevalence of heart failure, advancements in diagnostic accuracy, the expansion of homecare settings, a rising adoption of guideline-based therapies, and a concerted focus on minimizing hospital readmissions. Key trends observed in this period include an increasing embrace of combination drug therapies, a transition towards home-based heart failure management, a heightened emphasis on early diagnosis and continuous monitoring, the proliferation of chronic disease management programs, and the broadening of post-discharge care pathways.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

What Key Drivers Are Fueling The Growth Of The Congestive Heart Failure (CHF) Market?

The anticipated rise in cardiovascular patients is projected to boost the expansion of the congestive heart failure (CHF) market in the future. Cardiovascular pertains to the heart and blood vessels, emphasizing their function in blood circulation and preserving the body’s general health. This increase in cardiovascular patients stems from factors such as inactive lifestyles, poor dietary habits, an aging demographic, and growing urbanization, which consequently drives a greater demand for sophisticated healthcare and treatment options. Congestive heart failure (CHF) offers benefits to cardiovascular patients by delivering specific interventions designed to enhance heart function, alleviate symptoms, and avert complications, thereby improving patient care and general welfare. For example, as reported in January 2023 by the American College of Cardiology, a US-based nonprofit medical society, cardiovascular disease cases escalated to 19.8 million in 2022. Furthermore, Eastern Europe records the highest mortality rate, with 553 deaths per 100,000. Consequently, the growing number of cardiovascular patients is fueling the expansion of the congestive heart failure (CHF) market.

How Is The Congestive Heart Failure (CHF) Market Broken Down By Segment Categories?

The congestive heart failure (chf) market covered in this report is segmented –

1) By Type: Systolic Heart Failure, Diastolic Heart Failure, Left-Sided Heart Failure, Right-Sided Heart Failure

2) By Treatment: Medication, Surgery

3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings

Subsegments:

1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction

2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)

3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure

4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure

What Trends Are Influencing The Congestive Heart Failure (CHF) Market?

Leading companies in the congestive heart failure (CHF) market are concentrating on advanced innovations, such as single intracoronary infusion therapies, to provide effective treatment options that enhance heart function and improve the quality of life for CHF patients. Single intracoronary infusion administers medication directly into the coronary artery, precisely targeting the heart for conditions like congestive heart failure (CHF). For example, in January 2024, Bayer AG, a Germany-based pharmaceutics company, and Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, launched the GenePHIT Phase II trial for AB-1002, an investigational gene therapy intended for congestive heart failure (CHF). This innovation employs a gene therapy method to target non-ischemic cardiomyopathy, representing a potential breakthrough in the treatment of CHF through advanced genetic solutions. The trial is adaptive, double-blind, placebo-controlled, and aims to enroll between 90 and 150 participants who have maintained medical stability for at least four weeks and exhibit a left ventricular ejection fraction between 15% and 35%.

Which Players Are Present In The Congestive Heart Failure (CHF) Market Space?

Major companies operating in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic Plc, Canon Medical Systems Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova Plc, Edwards Lifesciences Corporation, Getinge AB, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, OSCOR Inc., Shree Pacetronix Ltd.

Get The Full Congestive Heart Failure (CHF) Market Report:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

Which Region Holds The Highest Market Share In The Congestive Heart Failure (CHF) Market?

North America was the largest region in the congestive heart failure (CHF) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (chf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Congestive Heart Failure (CHF) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2026, By The Business Research Company

Structural Heart Market Report 2026

https://www.thebusinessresearchcompany.com/report/structural-heart-global-market-report

Congestive Heart Failure Treatment Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-treatment-devices-global-market-report

Congenital Heart Disease Chd Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795